Search

Your search keyword '"Dario Ribera"' showing total 2 results
Start Over Author "Dario Ribera" Journal pharmaceutics
2 results on '"Dario Ribera"'

1. Selinexor and the Selective Inhibition of Nuclear Export: A New Perspective on the Treatment of Sarcomas and Other Solid and Non-Solid Tumors

Author

Antonella Lucia Marretta, Giuseppe Di Lorenzo, Dario Ribera, Lucia Cannella, Claudia von Arx, Alessandra Bracigliano, Ottavia Clemente, Roberto Tafuto, Antonio Pizzolorusso, and Salvatore Tafuto

Subjects
selinexor, XPO1, SINE, soft tissue sarcoma, metastatic cancer, multiple myeloma, Pharmacy and materia medica, RS1-441
Abstract

Nucleocytoplasmic transport has been found dysregulated in many types of cancer and is often described as a poor prognostic factor. Specifically, Exportin-1 (XPO1) has been found overexpressed in many tumors and has become an attractive target in molecular oncology and therapeutics development. The selective inhibitor of nuclear export, Selinexor, is one of the most scientifically interesting drugs that targets XPO1 in clinical development. In this review, we summarized the most relevant preclinical and clinical results achieved for non-solid tumors, sarcomas, and other kind of solid tumors.

Published
2021
Full Text
View/download PDF

2. Selinexor and the Selective Inhibition of Nuclear Export: A New Perspective on the Treatment of Sarcomas and Other Solid and Non-Solid Tumors

Author

Salvatore Tafuto, Antonio Pizzolorusso, Claudia von Arx, Lucia Cannella, Antonella Lucia Marretta, Dario Ribera, Giuseppe Di Lorenzo, Roberto Tafuto, Alessandra Bracigliano, and Ottavia Clemente

Subjects
Pharmaceutical Science, Review, Selective inhibition, Molecular oncology, XPO1, Pharmacy and materia medica, metastatic cancer, medicine, Nuclear export signal, Multiple myeloma, business.industry, target therapy, leukemia, Cancer, medicine.disease, SINE, RS1-441, multiple myeloma, Leukemia, Nucleocytoplasmic Transport, soft tissue sarcoma, Cancer research, gynecologic cancer, business, selinexor
Abstract

Nucleocytoplasmic transport has been found dysregulated in many types of cancer and is often described as a poor prognostic factor. Specifically, Exportin-1 (XPO1) has been found overexpressed in many tumors and has become an attractive target in molecular oncology and therapeutics development. The selective inhibitor of nuclear export, Selinexor, is one of the most scientifically interesting drugs that targets XPO1 in clinical development. In this review, we summarized the most relevant preclinical and clinical results achieved for non-solid tumors, sarcomas, and other kind of solid tumors.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results